KLRA Kailera Therapeutics, Inc.

Kailera Therapeutics (KLRA) said Wednesday that enrollment in the KaiNETIC global phase 3 clinical p

During the lightning round of the September 10 episode of Mad Money, a caller asked if Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a buy, sell, or hold. In response, Jim Cramer said: Okay, I actually know this, but okay, here’s the problem. Let’s say I say buy it. It’s just the most speculative stock on Earth. […]

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

Kailera Therapeutics (KLRA) is in focus after reporting a second quarter net loss of US$111.31 million and a six month net loss of US$190.17 million, alongside the appointment of Nur Nicholson as Chief Technology Officer. See our latest analysis for Kailera Therapeutics. The recent earnings update and leadership change come against a weaker backdrop for Kailera Therapeutics, with the share price at US$17.94 and the year to date share price return down 31%, suggesting momentum has been...

They are fairly risky, but their potential upside is massive.

Don't wait until clinical milestones send their share prices soaring.